trastuzumab deruxtecan
daiichi sankyo,astrazeneca
['pan-tumor', 'enhertu', 'daiichi', 'astrazeneca']
asco: astrazeneca, daiichi's enhertu delivers 'very compelling' pan-tumor activity, experts say 
Pharma’s go-to destination for news & trends shaping approved drugs. Delivering news, revealing insights straight to your inbox.